Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best fast money stocks to buy now. Clear Street assumed coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) with a ‘Buy’ rating and a price target of $100, implying a potential upside of nearly 172% from the current price. This optimism is driven by the company’s lead candidate, Claseprubart, which is what they refer to as a “best-in-class complement inhibitor.”

The research firm believes that Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is in a good position to enhance treatment standards in three autoimmune conditions undergoing clinical testing: generalized myasthenia gravis (gMG), chronic idiopathic demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN), with each of these representing a market of up to $2 billion.

While highlighting the company’s latest Phase 2 data in gMG, Clear Street noted the prospects surrounding CIDP and MMN, with data updates projected for the latter half of next year. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has already delivered a year-to-date return of 68.39%, outperforming the market average by an impressive 55.43%.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a New York-based clinical-stage biotechnology company offering solutions for patients living with severe autoimmune and inflammatory diseases. Founded in 2019, the company focuses on enhancing the selectivity of complement therapeutics.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.